Meng Li, ScM, Ph.D.
Department of Health Services Research, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Value of health care, pharmaceutical market and pricing, cancer health services research, population health equity.
Education & Training
Degree-Granting Education
| 2018 | University of Washington, Seattle, WA, USA, PHD, Pharmaceutical Outcomes Research and Policy |
| 2013 | Johns Hopkins University, Baltimore, MD, USA, ScM, Epidemiology |
| 2011 | Sun Yat-sen University, Guangzhou, CHN, BS, Pharmaceutical Sciences |
Postgraduate Training
| 2018-2020 | Postdoctoral Fellowship, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA |
Experience & Service
Other Appointments/Responsibilities
Nonresident Fellow, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, 2020 - Present
Health Economics and Outcomes Research Intern, Genentech, South San Francisco, CA, 2016 - Present
Research Assistant, Global Medicines Program, University of Washington, Seattle, WA, 2015 - 2016
Health Economics and Outcomes Research Consultant, VeriTech Corporation, Mercer Island, WA, 2015 - 2018
Health Economics and Outcomes Research Intern, GlaxoSmithKline, Seattle, WA, 2014 - Present
Research Assistant, Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Research Triangle Park, NC, 2013 - 2018
Clinical Trials Coordinator, Johns Hopkins University Center for Clinical Trials, Baltimore, MD, 2012 - 2013
Honors & Awards
| 2019 | Postdoctoral Scholar Training & Travel Award, University of Southern California |
| 2018 | Population Health Graduate Student Travel Award, University of Washington |
| 2017 | Rubenstein Endowment Award, University of Washington |
| 2015 | Reducing Barriers for the Ambitious Scholarship, University of Washington |
| 2013 | Top Scholar Awards, University of Washington |
| 2012 | Master’s Tuition Scholarship, The Johns Hopkins University |
| 2011 | Top Thesis Award, Sun Yat-sen University |
| 2007 | Top Scholar Scholarship, Sun Yat-sen University |
Selected Publications
Peer-Reviewed Articles
- Suk R, Liao K, Bauer CX, Basil C, Li M. Human Papillomavirus Vaccine Administration Trends Among Commercially Insured US Adults Aged 27-45 Years Before and After Advisory Committee on Immunization Practices Recommendation Change, 2007-2020. JAMA Health Forum 3(12):e224716, 2022. e-Pub 2022. PMID: 36525257.
- Li M, Liao K, Chen AJ, Cascone T, Shen Y, Lu Q, Shih YT. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. J Natl Cancer Inst. e-Pub 2022. PMID: 36346180.
- Li M, Liao K, Pan IW, Shih YT. Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer. JCO Oncol Pract 18(11):OP2200171, 2022. e-Pub 2022. PMID: 36099549.
- Elmore LC, Li M, Lin H, Shen Y, Shaitelman SF, Babiera G, Tamirisa N, Bedrosian I. Impact of Medicaid Expansion Under the Affordable Care Act on Receipt of Surgery for Breast Cancer. Ann Surg Open 3(3):e194, 2022. e-Pub 2022. PMID: 36199482.
- Lee W, Wong WB, Kowal S, Garrison LP, Veenstra DL, Li M. Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. Pharmacoeconomics 40(6):623-631, 2022. e-Pub 2022. PMID: 35527331.
- Zhao H, Duan Z, Li M, Chiao E, Ahmed S, Shih YT, Hwang JP. Increased Incidence of Human Papillomavirus-Related Precancer or Second Malignancy Among Allogeneic Stem Cell Transplantation Patients: A SEER-Medicare Population Study. Transplant Cell Ther 27(12):1016.e1-1016.e9, 2021. e-Pub 2021. PMID: 34474166.
- Li M, Bounthavong M. Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018. J Manag Care Spec Pharm 27(12):1750-1756, 2021. PMID: 34818087.
- Lee W, Li M, Wong WB, To TM, Garrison LP, Veenstra DL. Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. Value Health 24(12):1746-1753, 2021. e-Pub 2021. PMID: 34838272.
- Wong WB, To TM, Li M , Lee W, Veenstra DL, Garrison LP. Real-world evidence for option value in metastatic melanoma. J Manag Care Spec Pharm 27(11):1546-1555, 2021. e-Pub 2021. PMID: 34431715.
- Bounthavong M, Suh K, Li M, Spoutz PM, Stottlemyer BA, Sepassi A. Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017. Subst Abuse Treat Prev Policy 16(1):80, 2021. e-Pub 2021. PMID: 34670580.
- Lakdawalla D, Li M. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018. JAMA Netw Open 4(5):e219030, 2021. e-Pub 2021. PMID: 33950205.
- Li M, Goldman DP, Chen AJ. Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer. Health Aff (Millwood) 40(5):763-771, 2021. PMID: 33939503.
- Li M, Yeung K. Managing high-priced biologic agents: challenges and potential solutions. J Manag Care Spec Pharm 27(3):411-414, 2021. PMID: 33645239.
- Yang J, Cosman F, Stone PW, Li M, Nieves JW. Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?. Osteoporos Int 31(12):2321-2335, 2020. e-Pub 2020. PMID: 32778935.
- Garrison LP, Zamora B, Li M, Towse A. Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support. J Manag Care Spec Pharm 26(4):400-406, 2020. PMID: 32223599.
- Li M, Bounthavong M. Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey. J Gen Intern Med 35(4):1334-1336, 2020. e-Pub 2019. PMID: 31342322.
- Li M, Lakdawalla DN, Goldman DP. Association Between Spending and Outcomes for Patients With Cancer. J Clin Oncol 38(4):323-331, 2020. e-Pub 2019. PMID: 31804868.
- Li M, Basu A, Bennette C, Veenstra D, Garrison LP. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value Health 22(7):777-784, 2019. e-Pub 2019. PMID: 31277824.
- Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ 28(7):855-867, 2019. PMID: 31237095.
- Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. J Genet Couns 28(2):477-490, 2019. e-Pub 2018. PMID: 30964586.
- Xiao Y, Chen L, Jing D, Su J, Li M, Shen M, Chen X. Application and significance of willingness-to-pay in measuring the burden of skin diseases. Chinese Journal of Dermatology 52(4):286-289, 2019.
- Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasiima A, Kaganda P, Asiimwe FT, Vodicka E, Mugisha NM, Mukose A, Kwesiga DK, Lubinga SJ, Garrison LP, Babigumira JB. Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda. Papillomavirus Res 4:17-21, 2017. e-Pub 2017. PMID: 29179864.
- Yeung K, Li M, Carlson JJ. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. J Manag Care Spec Pharm 23(10):1010-1015, 2017. PMID: 28944729.
- Montenovo MI, Jalikis FG, Li M, Yeh M, Dick A, Hansen R, Reyes JD. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients. Exp Clin Transplant 15(4):425-431, 2017. e-Pub 2016. PMID: 27309029.
- Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP. Estimating the Cost of Illness of Giant Cell Arteritis in the United States. Rheumatol Ther 4(1):111-119, 2017. e-Pub 2017. PMID: 28084585.
- Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Res Social Adm Pharm 13(3):530-538, 2017. e-Pub 2016. PMID: 27263802.
- Jenny AM, Li M, Ashbourne E, Aldrink M, Funk C, Stergachis A. Assessment of the scope and practice of evaluation among medical donation programs. Global Health 12(1):69, 2016. e-Pub 2016. PMID: 27814729.
- Sibulesky L, Li M, Hansen RN, Dick AA, Montenovo MI, Rayhill SC, Bakthavatsalam R, Reyes JD. Impact of Cold Ischemia Time on Outcomes of Liver Transplantation: A Single Center Experience. Ann Transplant 21:145-51, 2016. e-Pub 2016. PMID: 26952540.
- Li M, Dick A, Montenovo M, Horslen S, Hansen R. Cost-effectiveness of liver transplantation in methylmalonic and propionic acidemias. Liver Transpl 21(9):1208-18, 2015. PMID: 25990417.
- Oh ES, Li M, Fafowora TM, Inouye SK, Chen CH, Rosman LM, Lyketsos CG, Sieber FE, Puhan MA. Preoperative risk factors for postoperative delirium following hip fracture repair: a systematic review. Int J Geriatr Psychiatry 30(9):900-10, 2015. e-Pub 2014. PMID: 25503071.
- Wu Y, Zhou Q, Xuan J, Li M, Zelt S, Huang Y, Yin H, Huang M. A Cost-Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China. Value Health Reg Issues 2(1):75-80, 2013. e-Pub 2013. PMID: 29702856.
- Lee W, Wong WB, Kowal S, Garrison LP, Veenstra DL, Li M. PharmacoEconomics. Modeling the ex ante clinical real option value in an innovative therapeutic area: ALK-positive non-small cell lung cancer.
Abstracts
- Lee W, Li M, Wong WB, Tu TM, Garrison LP, Veenstra DL. Modeling Approaches to Estimate Realized Real Option Value of Ipilimumab in Metastatic Melanoma. ISPOR Annual International Meeting, 2021.
- Wong WB, Tu TM, Li M, Lee W, Veenstra DL, Garrison LP. Podium presentation: Real-world evidence of option value in metastatic melanoma. ISPOR Annual International Meeting, 2021.
- Li M, Towse A, Grueger J. Issue panel: Real option value for drugs: is it really an option?. ISPOR Annual International Meeting, New Orleans, LA, 2019.
- Garrison L, Li M. Podium presentation: “It’s tough to make predictions, especially about the future”: comparing life expectancy predictions based on period versus cohort life tables. ISPOR Annual International Meeting, Baltimore, MD, 2018.
- Li M, Bennette C, Veenstra D, Basu A, Garrison L. Do investigational new drugs in the pipeline influence treatment decision-making of existing therapies? Insights from real options theory and real-world evidence from metastatic melanoma. SMDM Annual Meeting, Pittsburgh, PA, 2017.
- Babigumira J, Li M, Boudreau D, Best J, Garrison L. Estimating the Cost of Illness of Giant Cell Arteritis. ISPOR Annual International Meeting, Philadelphia, PA, 2015.
- Li M, Babigumira J, Boudreau D, Garrison L. Comparing Alternative Econometric Models for Estimating Healthcare Expenditures. Western Pharmacoeconomics and Outcomes Research Conference, Denver, CO, 2015.
- Li M. Podium presentation: An Economic Evaluation of Strategies for Reducing Treatment in Mild Persistent Asthma. American Thoracic Society International Conference, San Diego, CA, 2014.
Grant & Contract Support
| Title: | Immunotherapy Use in Metastatic Lung Cancer: Disparity, the Associated Factors, and Impact on Outcomes |
| Funding Source: | National Institute on Minority Health and Health Disparities |
| Role: | Principal Investigator |